PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q2 2019 13F Holders as of 30 Jun 2019

Type / Class
Equity / COM
Total 13F shares
67,151,457
Share change
-459,181
Total reported value
$414,048,433
Put/Call ratio
44%
Price per share
$6.17
Number of holders
138
Value change
-$334,800
Number of buys
63
Number of sells
59

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q2 2019

As of 30 Jun 2019, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 138 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 67,151,457 shares. The largest 10 holders included BlackRock Inc., Point72 Asset Management, L.P., FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, STATE STREET CORP, EAGLE ASSET MANAGEMENT INC, CARILLON TOWER ADVISERS, INC., RICE HALL JAMES & ASSOCIATES, LLC, PINNACLE ASSOCIATES LTD, and Bank of New York Mellon Corp. This page lists 138 institutional shareholders reporting positions in this security for the Q2 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.